Alimatravir vs Islatravir

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV-1 Reverse Transcriptase · full HIV pipeline

Alimatravir

Developed by Merck & Co.

Phase 3 in HIVsmall molecule
Weak signal

NCT06045507 · Phase 2 · completed

This randomized, double-blind, placebo-controlled Phase 2a study gave oral MK-8527 (alimatravir) once monthly at three doses or placebo to 352 adults at low risk of HIV-1 infection. Its stated purpose was safety, tolerability and pharmacokinetics, and both registered primary outcomes are adverse-event counts with no formal efficacy test, so there is no met or missed result. Source: CT.gov posted results. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With ≥1 Adverse Event (AE)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: January 2027 · NCT07600775 (registry estimate)

Reported efficacy

Number of Participants With ≥1 Adverse Event (AE) (Up to ~28 weeks); Number of Participants Discontinuing Study Therapy Due to Adverse Event (AE) (Up to ~20 weeks): Primary outcomes, safety (no formal efficacy test): participants with at least one adverse event 62/101 (3 mg), 69/101 (6 mg) and 66/99 (12 mg) monthly MK-8527 vs 31 on placebo; discontinuation due to an adverse event 0, 2 and 1 vs 2 (CT.gov posted results). (not_applicable)

Result source: NCT06045507

Islatravir

Developed by Merck & Co.

Phase 3 in HIVsmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2027 · NCT06891066 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlimatravirIslatravir
HIV-1 RNA below 50 copies/mL (week 48)—Trial running · NCT07044297—Trial running · NCT07266831
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT07044297—Trial running · NCT07266831
CD4 count, change (week 48)—Trial running · NCT07044297—Trial running · NCT07266831

HIV-1 RNA below 50 copies/mL (week 48)

Alimatravir
—Trial running · NCT07044297
Islatravir
—Trial running · NCT07266831

HIV-1 RNA 50 copies/mL or more (week 48)

Alimatravir
—Trial running · NCT07044297
Islatravir
—Trial running · NCT07266831

CD4 count, change (week 48)

Alimatravir
—Trial running · NCT07044297
Islatravir
—Trial running · NCT07266831
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Alimatravir: 3 of 4 rows · Islatravir: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlimatravirIslatravir
Dropout rate
2%12 mg QMa
NCT06045507 · Phase 2
show 9 more results
4.9%6 mg QM
NCT06045507 · Phase 2
8.9%3 mg QM
NCT06045507 · Phase 2
0%1.0 mg
NCT05494736 · Phase 1 · registry result, not featured evidence
0%0.5 mg
NCT05494736 · Phase 1 · registry result, not featured evidence
0%0.25 mg
NCT05494736 · Phase 1 · registry result, not featured evidence
—0.25 mg
NCT05494736 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT03615183 · Phase 1 · registry result, not featured evidence
0%3 mg
NCT03615183 · Phase 1 · registry result, not featured evidence
0%1 mg
NCT03615183 · Phase 1 · registry result, not featured evidence
5%400 mg weeklya
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
show 11 more results
—400 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
—400 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
4.9%200 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
—200 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
—200 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
7.5%100 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
—100 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
—100 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
6.2%120 mg
NCT04003103 · Phase 2 · registry result, not featured evidence
15.5%60 mg
NCT04003103 · Phase 2 · registry result, not featured evidence
0%
NCT04515641 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—12 mg QMa
NCT06045507 · Phase 2
show 9 more results
—6 mg QM
NCT06045507 · Phase 2
—3 mg QM
NCT06045507 · Phase 2
—1.0 mg
NCT05494736 · Phase 1 · registry result, not featured evidence
—0.5 mg
NCT05494736 · Phase 1 · registry result, not featured evidence
—0.25 mg
NCT05494736 · Phase 1 · registry result, not featured evidence
—0.25 mg
NCT05494736 · Phase 1 · registry result, not featured evidence
—10 mg
NCT03615183 · Phase 1 · registry result, not featured evidence
—3 mg
NCT03615183 · Phase 1 · registry result, not featured evidence
—1 mg
NCT03615183 · Phase 1 · registry result, not featured evidence
—400 mg weeklya
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
show 11 more results
—400 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
—400 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
—200 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
—200 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
—200 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
—100 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
—100 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
—100 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
—120 mg
NCT04003103 · Phase 2 · registry result, not featured evidence
—60 mg
NCT04003103 · Phase 2 · registry result, not featured evidence
—
NCT04515641 · Phase 1 · registry result, not featured evidence
Serious AEs
1%12 mg QMa
NCT06045507 · Phase 2
show 9 more results
0%6 mg QM
NCT06045507 · Phase 2
2%3 mg QM
NCT06045507 · Phase 2
0%1.0 mg
NCT05494736 · Phase 1 · registry result, not featured evidence
0%0.5 mg
NCT05494736 · Phase 1 · registry result, not featured evidence
—0.25 mg
NCT05494736 · Phase 1 · registry result, not featured evidence
0%0.25 mg
NCT05494736 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT03615183 · Phase 1 · registry result, not featured evidence
0%3 mg
NCT03615183 · Phase 1 · registry result, not featured evidence
0%1 mg
NCT03615183 · Phase 1 · registry result, not featured evidence
—400 mg weeklya
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
show 11 more results
2.5%400 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
2.7%400 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
—200 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
7.3%200 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
0%200 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
—100 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
5%100 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
0%100 mg weekly
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
0%120 mg
NCT04003103 · Phase 2 · registry result, not featured evidence
1%60 mg
NCT04003103 · Phase 2 · registry result, not featured evidence
0%
NCT04515641 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
12 mg QMa
upper respiratory tract infection 10.1% (placebo 12.2%)
fatigue 7.1% (placebo 6.1%)
lymphocyte count decreased 6.1% (placebo 2%)
NCT06045507 · Phase 2
show 8 more results
6 mg QM
upper respiratory tract infection 9.9% (placebo 12.2%)
fatigue 7.9% (placebo 6.1%)
nausea 7.9% (placebo 2%)
NCT06045507 · Phase 2
3 mg QM
upper respiratory tract infection 15.8% (placebo 12.2%)
headache 8.9% (placebo 0%)
cough 5% (placebo 0%)
NCT06045507 · Phase 2
1.0 mg
headache 25%
blood pressure increased 12.5%
conjunctivitis allergic 12.5%
NCT05494736 · Phase 1 · registry result, not featured evidence
0.5 mg
anogenital warts 16.7%
carbuncle 16.7%
dermatitis contact 16.7%
NCT05494736 · Phase 1 · registry result, not featured evidence
0.25 mg
dyspepsia 16.7%
dyspnoea 16.7%
headache 16.7%
NCT05494736 · Phase 1 · registry result, not featured evidence
10 mg
dizziness 0%
insomnia 0%
pharyngitis 0%
NCT03615183 · Phase 1 · registry result, not featured evidence
3 mg
dizziness 16.7%
insomnia 16.7%
pharyngitis 16.7%
NCT03615183 · Phase 1 · registry result, not featured evidence
1 mg
dizziness 0%
insomnia 0%
pharyngitis 0%
NCT03615183 · Phase 1 · registry result, not featured evidence
400 mg weeklya
covid-19 17.5%
diarrhoea 15%
fatigue 12.5%
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
show 8 more results
400 mg weekly
covid-19 29.7%
arthralgia 5.4%
fatigue 5.4%
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
200 mg weekly
covid-19 9.8%
asthenia 7.3%
diarrhoea 7.3%
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
200 mg weekly
covid-19 17.9%
back pain 5.1%
bronchitis 5.1%
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
100 mg weekly
headache 12.5%
fatigue 10%
covid-19 7.5%
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
100 mg weekly
covid-19 10.8%
diarrhoea 5.4%
sinusitis 5.4%
NCT04564547 · Phase 2 · registry result, not featured evidence · combination
120 mg
headache 9.3% (placebo 4.2%)
nausea 7.2% (placebo 4.2%)
blood pressure increased 5.2% (placebo 0%)
NCT04003103 · Phase 2 · registry result, not featured evidence
60 mg
headache 10.3% (placebo 4.2%)
diarrhoea 5.2% (placebo 8.3%)
nausea 5.2% (placebo 4.2%)
NCT04003103 · Phase 2 · registry result, not featured evidence
headache 16.7%
NCT04515641 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Alimatravir

HIV-1 RNA -1.38 copies/mL @ 1wk1.0 mg
absolute change · copies/mL
No placebo or comparator arm
NCT05494736 · Phase 1 · registry result, not featured evidence
show 2 more results
-1.4 copies/mL @ 1wk0.5 mg
NCT05494736 · Phase 1 · registry result, not featured evidence
-0.8 copies/mL @ 1wk0.25 mg
NCT05494736 · Phase 1 · registry result, not featured evidence
HIV-1 RNA -1.39 log @ 1wk10 mg
absolute change · log
No placebo or comparator arm
NCT03615183 · Phase 1 · registry result, not featured evidence
show 2 more results
-1.66 log @ 1wk3 mg
NCT03615183 · Phase 1 · registry result, not featured evidence
-0.95 log @ 1wk1 mg
NCT03615183 · Phase 1 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alimatravir's landscape · Islatravir's landscape